We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.51B
1-Year Est. Return 546.08%
This Fund
S&P 500
This Quarter Est. Return
+32.66%
1 Year Est. Return
+546.08%
3 Year Est. Return
+2,136.34%
5 Year Est. Return
+8,050.66%
10 Year Est. Return
–
AUM
$1.51B
AUM Growth
+$129M
Cap. Flow
-$167M
Cap. Flow %
-11.04%
Top 10 Hldgs %
97.65%
Holding
13
New
1
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$19M
2
FTH
Faeth Therapeutics
FTH
+$16.7M

Top Sells

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$203M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

Similar funds

AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
DAM
DLD Asset Management New York $1.51B AUM 5.32% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.51B AUM 85.85% 1-Year Est. Return
NB
NBT Bank Norwich, New York $1.51B AUM 24.9% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
SC
Styrax Capital New York $1.52B AUM 57.44% 1-Year Est. Return
RIM
Rush Island Management New York $1.51B AUM 8.12% 1-Year Est. Return
WFA
Wellspring Financial Advisors Cleveland, Ohio $1.52B AUM 29.68% 1-Year Est. Return

Fairmount Funds Management's Q2 2026 Portfolio in Review

As of Q2 2026, Fairmount Funds Management held 13 positions worth $1.51B, up 9.3% from $1.38B the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Fairmount Funds Management withdrew a net $167M in Q2 2026, closing 1 position. Its most notable exit was Spyre Therapeutics, an estimated $203M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Fairmount Funds Management opened a new position in Faeth Therapeutics worth $18.1M.

  • Fairmount Funds Management's largest Q2 2026 buy was Faeth Therapeutics: 722,020 shares worth $18.1M.
  • Fairmount Funds Management added most to Viridian Therapeutics in Q2 2026, an estimated $19M increase.
  • Fairmount Funds Management fully exited Spyre Therapeutics in Q2 2026, selling an estimated $203M.
  • Fairmount Funds Management's ten largest holdings make up 98% of its $1.51B portfolio in Q2 2026.
  • Fairmount Funds Management opened 1 new position and closed 1 in Q2 2026.
  • Fairmount Funds Management's portfolio value rose 9.3% quarter-over-quarter to $1.51B.

Based on Fairmount Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.